武肺疫情輾轉覆轍,加上唔少人士直到依一刻依然唔信武肺存在,又或者唔怕武肺唔戴口罩、「我生病我的事」,導致感染人數經常出現技術性反彈。807Please respect copyright.PENANAVZJ4qGaGnV
807Please respect copyright.PENANAig2v1h3iUY
武肺疫苗一直被媒體渲染為扭轉全球疫情的唯一辦法,但實際上一直黑過黑森林的黑馬一直在漆黑中默默奔跑,隨時會跑快過各種疫苗率先進入市場。807Please respect copyright.PENANAXiRfy606Yo
807Please respect copyright.PENANAxPBzuaOScW
依一隻黑馬,就係人造抗體。807Please respect copyright.PENANAFLxQDErZmU
807Please respect copyright.PENANAxMLQBXnuaZ
疫苗的最終目的,就係想誘導人體自行製造抗體,達收拾武肺之效。807Please respect copyright.PENANA14D7bupfZ0
807Please respect copyright.PENANA6GDwnshKkS
有唔少生物科技公司認為,與其花費時間製造疫苗,倒不如以人造的方式製作疫苗的最終產物「抗體」,豈不是更加直接快捷?807Please respect copyright.PENANAq4qlY2cTrU
807Please respect copyright.PENANAhP0YS99nNF
就喺今年六月初,禮來公司(Lilly)宣佈進行人造抗體LY-Cov555的Phase1臨床測試(Ref1),LY-Cov555係一隻針對武肺S protein位置的人造抗體,簡單啲嚟講,佢主要功用就係黏住武肺病毒與人體細胞的接觸面,令到病毒無辦法辨認細胞,失去入侵人體細胞的手段。807Please respect copyright.PENANALmpkCpDTaL
807Please respect copyright.PENANAXNibpwh0n9
除禮來之外,雷傑納榮製藥(Regeneron)亦宣佈即將會進行Phase3臨床試驗,佢哋將會以人造方式製造一名武肺康復人士的抗體再加以一隻由老鼠而嚟的武肺抗體,用上二合一的方式進行測試(Ref2)。807Please respect copyright.PENANAzt5h9yl3JF
807Please respect copyright.PENANAdlHa56HPum
佢哋所製作的人造抗體有學術文章指出,將能夠辨認得到現今的所有武肺變種,包括時下大流行的D614G變種,聽起上嚟的確非常令人振奮。807Please respect copyright.PENANAVq9ebxdIcW
807Please respect copyright.PENANAAAxHcIzm1O
而最值得注意的係,人造抗體的臨床治療所需時間一般會比疫苗的臨床治療為快。原因係就疫苗嚟講,通常要一定的時間過後身體免疫系統先會開始製造抗體,隨後先可以進行測試。807Please respect copyright.PENANA07QRBeNi11
807Please respect copyright.PENANAM99N9DhBmv
但人造抗體只要一注射入體內,有就有,無就無,相對上好快就可以進行所需的測試。807Please respect copyright.PENANAUk6zvyMOCW
807Please respect copyright.PENANAipGvBKpmIz
所以呢,人造抗體依一隻黑馬,絕對係有機會跑快過疫苗進入商業市場的。807Please respect copyright.PENANA5iNqYQrdZW
807Please respect copyright.PENANAlmyEhIEAsJ
不過當然,論長遠嚟講,疫苗絕對比人造抗體更能提供更長遠及實際的保護效果。807Please respect copyright.PENANArOOJcuh6r1
但就當今現時局勢嚟講,疫苗某程度上只係「遠水」,人造抗體先係「近水」,有效撲滅武肺「近火」。807Please respect copyright.PENANAogUQZYgXHk
807Please respect copyright.PENANAyj6al4E8CG807Please respect copyright.PENANA1LSBrQqlrf
某兩款康復病人對抗武肺抗體(綠色及橙色)的示意圖,白色為武肺與人體細胞接觸所需的S protein。裡頭的紅點及藍點為現今所知的武肺變種位置,無一個變種位置可以阻撓抗體與其結合。807Please respect copyright.PENANAAAG8XQ06a2
807Please respect copyright.PENANA1RvFqhg0Gm
Ref1: https://investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody807Please respect copyright.PENANAuIRBKedvIY
Ref2: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-start-regn-cov2-phase-3-covid-19-prevention/807Please respect copyright.PENANADF82poFSS8